News About SaNOtize Nasal Spray (Enovid)

What Is Enovid, and How Does It Work? A Deep Dive into Its Science and Applications

On March 05, 2024 0 Comment

What is Enovid? Many people have heard of the medication, and it’s time to learn more about it. Enovid contains nitric oxide (NO). Scientists fully understand NO and have studied the nano-molecule, which is found naturally in the body. It features many physiologic functions, such as regulating a person’s immune system and dilating their blood vessels. Initially, Enovid was introduced for therapeutic approval in 1999 to treat blue baby syndrome, which is persistent pulmonary hypertension in newborns. Scientists have studied nitric oxide for many decades, determining that it features strong antimicrobial properties against various pathogens. When you deliver NO to...

SaNotize Enovid Nasal Spray: A Powerful Defense Against COVID Variants, Flu, and Cold Viruses

On December 05, 2023 0 Comment

Introduction to SaNotize Enovid Nasal Spray In these challenging times of COVID-19, it has become more important than ever to protect our health and that of our loved ones from the threat of COVID variants, flu, and cold viruses. One powerful defense that has emerged is the SaNotize Enovid Nasal Spray, which you can buy online. This innovative enovid spray is designed to provide effective antiviral protection, bolstering our immune system against various respiratory viruses, including COVID variants, flu, and cold viruses. In this article, we will explore the science behind SaNotize Enovid Nasal Spray, its benefits, and how it...

Gilly Regev and Chris Miller write about The Power of Nitric Oxide on MedCityNews.com

On January 23, 2023 0 Comment

"The Power of NO: How a Tiny Natural Molecule Can Help Shift How We Treat Covid-19 and Other Infections While more work needs to be done, the current research into new delivery platforms for nitric oxide is extremely promising. We hope to see the molecule play an increasingly prominent role in treatment and prevention strategies for common infections – and in so doing help provide greater access to healthcare globally." Published on Jan 4th, 2023 on MedCityNews.com, By Gilly Regev and Chris Miller Click here to read the full article

The Jerusalem Post: Can an anti-viral nasal spray stop Corona and other viruses?

On January 23, 2023 0 Comment

"Enovid, an innovative anti-viral spray developed in Canada by an Israeli researcher and manufactured in Israel, has been proven effective in preventing viruses – including COVID-19 – from entering the body through the nasal cavity." Published: JANUARY 3, 2023 12:13 on the Jerusalem post, click to READ MORE

SaNOtize moves to carve a new market demand: over-the-counter prevention

On September 22, 2022 0 Comment

There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October. It’s a deviation for the company that until now has been developing the nitric oxide nasal spray (NONS) as an early antiviral treatment, primarily assessing a reduction in viral load and testing time. But the takeaway from the company’s July 18 meeting with regulators was that those two markers wouldn’t be sufficient primary endpoints in a phase 3 treatment trial over a reduction...

SaNOtize raised $24M to fund phase 3 trial of COVID-19 nasal spray

On September 22, 2022 0 Comment

SaNOtize has raised a $24 million series B round, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial and other research into its nitric oxide nasal spray (NONS). The Vancouver-based company set up shop in 2017 to unlock the antimicrobial properties of nitric oxide. Using its nitric oxide releasing solution platform, SaNOtize sought to enable the use of the molecule in sprays, baths, lavages, gels and creams. Interest in the platform went up a gear in 2020 when COVID-19 created a pressing need for interventions capable of treating and preventing SARS-CoV-2 infection. Published by Nick Paul Taylor on Aug...